In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

The next year will probably bring additional volatility to the industry. Note that the weight loss leaders, Eli Lilly (LLY) ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

In today's video, I will look at four stocks that have seen meaningful pullbacks and now appear undervalued. In a stock ...

If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...

Cornell researchers have developed an implant system that can treat Type 1 diabetes by supplying extra oxygen to densely ...